sb 202190 has been researched along with Idiopathic Parkinson Disease in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Excerpt | Relevance | Reference |
|---|---|---|
| " PD is treated with chronic administration of l-3,4-dihydroxyphenylalanine (levodopa, L-DOPA), and typically, increasing doses are used during progression of the disease." | 1.37 | Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease. ( Liedhegner, EA; Mieyal, JJ; Steller, KM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liedhegner, EA | 1 |
| Steller, KM | 1 |
| Mieyal, JJ | 1 |
1 other study available for sb 202190 and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.
Topics: Anthracenes; Antiparkinson Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopaminerg | 2011 |